Aligos Therapeutics
ALGS
48 hedge funds and large institutions have $45.3M invested in Aligos Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
25% more capital inflows, than outflows
Capital inflows: $3.49M | Capital outflows: $2.8M
23% more funds holding
Funds holding: 39 → 48 (+9)
0.55% more ownership
Funds ownership: 63.13% → 63.67% (+0.55%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.96M |
| 2 |
UBS O'Connor
Chicago,
Illinois
|
+$398K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$265K |
| 4 |
Renaissance Technologies
New York
|
+$254K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$228K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.3M |
| 2 |
Tang Capital Management
San Diego,
California
|
-$430K |
| 3 |
NM
Newtyn Management
New York
|
-$43.8K |
| 4 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$10.3K |
| 5 |
Two Sigma Securities
New York
|
-$9.8K |
ALGS Hedge Fund Activity: Q1 2024 in Review
48 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2024, worth a combined $45.3M — up 50% from $30.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALGS positions and 2 closed out — a net gain of 9 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.96M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.3M sold.
- 48 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2024, up from 39 in Q4 2023.
- Funds reported $45.3M of Aligos Therapeutics stock for Q1 2024, up 50% quarter-over-quarter.
- 11 funds opened new Aligos Therapeutics positions in Q1 2024 and 2 closed out, a net change of +9 holders.
- The largest Aligos Therapeutics buyer in Q1 2024 was Adage Capital Partners, an estimated $1.96M added.
- The largest Aligos Therapeutics seller in Q1 2024 was Alyeska Investment Group, an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2024.